Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting 2024Phase 2 randomized trial in PDAC is underway with enrollment expected to complete in the fourth quarter of 2024ELI-002 7P initial clinical trial data expected in the second quarter of 2024Private placement with gross proceeds of $6.0 million closed in March 2024 BOSTON, March 29, 2024 (GLOBE ...